Print Page  |  Close Window

SEC Filings

PROTAGONIST THERAPEUTICS, INC filed this Form 8-K on 03/07/2017
Entire Document

Exhibit 99.1



Protagonist Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results

- Phase 2b Trial Underway for PTG-100 in Ulcerative Colitis

- PTG-200 & PTG-300 Expected to Enter the Clinic in 2017

Milpitas, CA (March 7, 2017): Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today reported its financial results for the fourth quarter and full year ended December 31, 2016 and provided an update on the company’s recent achievements.

“In 2016 Protagonist successfully made the transition from a private company to a NASDAQ listed public company, completing an approximately $83.6 million net raise in an upsized initial public offering,” Dinesh V. Patel, Ph.D., Protagonist President and Chief Executive Officer, commented, “The success of the IPO was driven by positive Phase 1 clinical proof-of-concept data for PTG-100, coupled with the current and future potential of our proprietary peptide technology platform and pre-clinical assets PTG-200 and PTG-300.”

“In January 2017,” continued Dr. Patel, “we dosed our first patient in the PTG-100 Phase 2b clinical trial for ulcerative colitis, for which we anticipate an interim futility analysis in the second half of the year.”

Protagonist plans to commence Phase 1 studies for PTG-200 and PTG-300, with top-line, clinical proof-of-concept data for PTG-300 expected in the second half of 2017. All three assets in clinical development have emerged from Protagonist’s proprietary peptide technology platform, which the company will continue to utilize to discover new peptide-based drugs.

Additional 2016 and Recent Business Highlights:


    Presented preclinical data on PTG-100 and PTG-200 at Digestive Disease Week (DDW) in May 2016 and at the European Crohn’s and Colitis Organization Congress in February 2017.


    Received a Phase 1 Small Business Innovation Research (SBIR) Grant from the National Institute of Heart and Lung Diseases of the National Institutes of Health in July 2016 to fund the development of injectable hepcidin mimetics for the treatment of iron overload disorders.


    Presented two posters detailing Phase 1 clinical and pre-clinical data for PTG-100 at the United European Gastroenterology (UEG) Week in October 2016.


    Received notice for a key patent, No. 9,518,091, issued covering orally stable peptides from the company’s most advanced development program in January 2017. This patent together with previously granted U.S. patent No. 9,273,093, provides protection for the company’s alpha4beta7 integrin peptide inhibitors, including PTG-100.